Acumen Pharmaceuticals, Inc. quarterly report, Q3 FY2023

Business context and reporting period

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ACU193, an antibody designed to target soluble amyloid-beta oligomers in Alzheimer’s disease. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2023. The company had no product revenue and remains dependent on external financing.

Key financial metrics

As a pre-revenue company, operating and profit margins are not meaningful. Management estimated that cash, cash equivalents and marketable securities, together with the $30.0 million loan tranche received after quarter-end, would fund operations into the second half of 2026, subject to assumptions that may prove inaccurate.

Changes versus the prior comparable period

• Q3 operating expenses increased 41% year over year; R&D rose 35% and G&A rose 59%. Nine-month operating expenses increased 38%.
• Q3 net loss increased 21% year over year to $13.0 million; nine-month net loss increased 20% to $35.9 million.
• Higher research and development spending reflected personnel, materials, consulting and Phase 2 planning costs. G&A growth reflected personnel, stock compensation, consulting and professional fees.
• Interest income increased to $3.1 million in Q3 and $6.8 million for the first nine months, principally due to higher interest rates and the larger securities portfolio.
• On July 21, 2023, the company raised $122.3 million net by issuing 16.8 million shares at $7.75 per share, increasing shares outstanding and diluting existing holders.

Outlook, developments and risks

• Management expects expenses and operating losses to rise as ACU193 advances through clinical development. The company expects to need additional financing to complete trials and, if approved, commercialize its candidates.
• Following FDA discussions in Q4 2023, the company reported no objection to proceeding with a Phase 2/3 study and planned to start its Phase 2 portion in the first half of 2024. It said timing and data from Phase 2 interim readouts would not be publicly disclosed to protect study integrity.
• July 2023 topline results from INTERCEPT-AD, a Phase 1 trial, were reported to meet primary and secondary objectives in 60 participants. The company described dose-related target engagement and plaque-load reductions at higher doses. The trial was small and short; exploratory measures did not show discernible immediate effects on cognition or cerebral blood flow.
• Reported adverse events included ARIA-E in 10.4% of participants, including one symptomatic case, and ARIA-H in 8.3%. Three serious treatment-emergent events were judged unrelated or unlikely related to ACU193. Further clinical testing is needed to establish safety and efficacy.
• On November 5, 2023, Acumen entered a Halozyme license agreement to develop a subcutaneous ACU193 formulation. Terms include a seven-figure upfront payment, development and sales milestones, and single-digit royalties.
• On November 10, 2023, Acumen received a $30.0 million first tranche under a loan facility of up to $50.0 million; the additional $20.0 million is subject to lender review and discretionary approval. The loan bears interest at the greater of 9.65% or prime plus 1.15%, is secured by substantially all assets except intellectual property, and includes covenants. A warrant covers up to 730,769 shares at $1.95 per share.
• Key risks include clinical and regulatory uncertainty, the ability to secure future funding on acceptable terms, potential dilution or debt restrictions, reliance on third-party manufacturers and trial providers, and competition. No material legal proceedings were reported. Management stated disclosure controls were effective as of September 30, 2023.

Important facts for investors to verify

• Whether ACU193’s Phase 2/3 trial starts on the planned schedule and what the protocol, enrollment and milestones entail.
• How much of the reported Phase 1 efficacy and biomarker evidence is confirmed in larger, longer studies, and how safety events develop with continued dosing.
• Whether the company’s runway estimate remains valid as clinical spending increases, and what assumptions underpin the second-half-2026 estimate.
• The full loan agreement, including covenants, repayment and prepayment terms, and the conditions for accessing the remaining $20.0 million.
• The financial impact and development timeline of the Halozyme agreement, including upfront, milestone and royalty obligations.
• Future financing needs and the potential effect of additional equity issuance, convertible debt or other dilution on existing shareholders.